Cargando…

Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial

BACKGROUND: Challenges in clinical trial recruitment threaten the successful development of improved therapies. This is particularly true in Parkinson’s disease (PD) studies of disease modification where the population of interest is difficult to find and study design is more complex. OBJECTIVE: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Berk, Sarah, Greco, Brittany L., Biglan, Kevin, Kopil, Catherine M., Holloway, Robert G., Meunier, Claire, Simuni, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676860/
https://www.ncbi.nlm.nih.gov/pubmed/29103052
http://dx.doi.org/10.3233/JPD-171199
_version_ 1783277143444160512
author Berk, Sarah
Greco, Brittany L.
Biglan, Kevin
Kopil, Catherine M.
Holloway, Robert G.
Meunier, Claire
Simuni, Tanya
author_facet Berk, Sarah
Greco, Brittany L.
Biglan, Kevin
Kopil, Catherine M.
Holloway, Robert G.
Meunier, Claire
Simuni, Tanya
author_sort Berk, Sarah
collection PubMed
description BACKGROUND: Challenges in clinical trial recruitment threaten the successful development of improved therapies. This is particularly true in Parkinson’s disease (PD) studies of disease modification where the population of interest is difficult to find and study design is more complex. OBJECTIVE: This paper seeks to understand how STEADY PD III, a National Institute of Neurological Disorders and Stroke (NINDS) funded phase 3 trial evaluating the efficacy of isradipine as a disease modifying agent for PD, was able to recruit their full target population 6 months ahead of schedule. METHODS: STEADY PD III aimed to enroll 336 individuals with early stage idiopathic PD within 18 months using 57 sites across the United States and Canada. The study included a 10% NIH minority recruitment goal. Eligible participants agreed to be followed for up to 36 months, complete 12 in-person visits and 4 telephone visits. A Recruitment Committee of key stakeholders was critical in the development of a comprehensive recruitment strategy involving: multi-modal outreach, protocol modifications and comprehensive site selection and activation. Efforts to increase site-specific minority recruitment strategies were encouraged through additional funding. RESULTS: A total of 336 individuals, including 34 minorities, were enrolled within 12 months – 6 months ahead of the projected timeline. Quantitative analysis of recruitment activity questionnaires found that of the sites that completed them (n = 54), (20.4%) met goals, (24.1%) exceeded goals, and (55.6%) fell below projected goals. Referral sources completed at time of screening indicate top four study referral sources as: site personnel (53.8%); neurologists (24%); Fox Trial Finder (10.2%); and communications from The Michael J. Fox Foundation (3.9%). CONCLUSIONS: STEADY PD III serves as an important example of methods that can be used to increase clinical trial recruitment. This research highlights a continued need to improve site infrastructure and dedicate more resources to increased participation of minorities in clinical research.
format Online
Article
Text
id pubmed-5676860
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-56768602017-11-16 Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial Berk, Sarah Greco, Brittany L. Biglan, Kevin Kopil, Catherine M. Holloway, Robert G. Meunier, Claire Simuni, Tanya J Parkinsons Dis Research Report BACKGROUND: Challenges in clinical trial recruitment threaten the successful development of improved therapies. This is particularly true in Parkinson’s disease (PD) studies of disease modification where the population of interest is difficult to find and study design is more complex. OBJECTIVE: This paper seeks to understand how STEADY PD III, a National Institute of Neurological Disorders and Stroke (NINDS) funded phase 3 trial evaluating the efficacy of isradipine as a disease modifying agent for PD, was able to recruit their full target population 6 months ahead of schedule. METHODS: STEADY PD III aimed to enroll 336 individuals with early stage idiopathic PD within 18 months using 57 sites across the United States and Canada. The study included a 10% NIH minority recruitment goal. Eligible participants agreed to be followed for up to 36 months, complete 12 in-person visits and 4 telephone visits. A Recruitment Committee of key stakeholders was critical in the development of a comprehensive recruitment strategy involving: multi-modal outreach, protocol modifications and comprehensive site selection and activation. Efforts to increase site-specific minority recruitment strategies were encouraged through additional funding. RESULTS: A total of 336 individuals, including 34 minorities, were enrolled within 12 months – 6 months ahead of the projected timeline. Quantitative analysis of recruitment activity questionnaires found that of the sites that completed them (n = 54), (20.4%) met goals, (24.1%) exceeded goals, and (55.6%) fell below projected goals. Referral sources completed at time of screening indicate top four study referral sources as: site personnel (53.8%); neurologists (24%); Fox Trial Finder (10.2%); and communications from The Michael J. Fox Foundation (3.9%). CONCLUSIONS: STEADY PD III serves as an important example of methods that can be used to increase clinical trial recruitment. This research highlights a continued need to improve site infrastructure and dedicate more resources to increased participation of minorities in clinical research. IOS Press 2017-11-01 /pmc/articles/PMC5676860/ /pubmed/29103052 http://dx.doi.org/10.3233/JPD-171199 Text en © 2017 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Berk, Sarah
Greco, Brittany L.
Biglan, Kevin
Kopil, Catherine M.
Holloway, Robert G.
Meunier, Claire
Simuni, Tanya
Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
title Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
title_full Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
title_fullStr Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
title_full_unstemmed Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
title_short Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial
title_sort increasing efficiency of recruitment in early parkinson’s disease trials: a case study examination of the steady-pd iii trial
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676860/
https://www.ncbi.nlm.nih.gov/pubmed/29103052
http://dx.doi.org/10.3233/JPD-171199
work_keys_str_mv AT berksarah increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial
AT grecobrittanyl increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial
AT biglankevin increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial
AT kopilcatherinem increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial
AT hollowayrobertg increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial
AT meunierclaire increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial
AT simunitanya increasingefficiencyofrecruitmentinearlyparkinsonsdiseasetrialsacasestudyexaminationofthesteadypdiiitrial